BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Kyowa Kirin readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Kyowa Kirin's drugs run\, from Cl
 inicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05692180-1322@assetmemo.bio
DTSTAMP:20261121T005007Z
DTSTART;VALUE=DATE:20261223
DTEND;VALUE=DATE:20261224
SUMMARY:Fasenra (Benralizumab): Phase 3 readout est. (NCT05692180)
DESCRIPTION:Fasenra (Benralizumab)\, phase 3\, Asthma.\nStudy: A Multicentr
 e\, Randomised\, Double-blind\, Parallel Group\, Placebo-controlled\, Time
 -to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benra
 lizumab in Paediatric Patients With Severe Eosinophilic Asthma\nEstimated 
 primary completion: 23 December 2026. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/benralizumab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT05692180
URL:https://assetmemo.bio/drug/benralizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07623616-2835@assetmemo.bio
DTSTAMP:20261121T005007Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Ziftomenib: Phase 2 readout est. (NCT07623616)
DESCRIPTION:Ziftomenib\, phase 2\, Acute Myeloid Leukemia.\nStudy: A Phase 
 2 Clinical Study of Ziftomenib in Patients With Relapsed or Refractory NPM
 1-Mutated Acute Myeloid Leukemia\nEstimated primary completion: March 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/ziftomenib#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07623616
URL:https://assetmemo.bio/drug/ziftomenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06512883-1322@assetmemo.bio
DTSTAMP:20261121T005007Z
DTSTART;VALUE=DATE:20280220
DTEND;VALUE=DATE:20280221
SUMMARY:Fasenra (Benralizumab): Phase 3 readout est. (NCT06512883)
DESCRIPTION:Fasenra (Benralizumab)\, phase 3.\nStudy: A Trial to Investigat
 e Benralizumab in Children With Eosinophilic Diseases\nEstimated primary c
 ompletion: 20 February 2028. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/benralizumab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06512883
URL:https://assetmemo.bio/drug/benralizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04067336-2835@assetmemo.bio
DTSTAMP:20261121T005007Z
DTSTART;VALUE=DATE:20281016
DTEND;VALUE=DATE:20281017
SUMMARY:Ziftomenib: Phase 1/2 readout est. (NCT04067336)
DESCRIPTION:Ziftomenib\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: First 
 in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leuke
 mia\nEstimated primary completion: 16 October 2028. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/ziftomenib#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT04067336
URL:https://assetmemo.bio/drug/ziftomenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07444567-1322@assetmemo.bio
DTSTAMP:20261121T005007Z
DTSTART;VALUE=DATE:20291227
DTEND;VALUE=DATE:20291228
SUMMARY:Fasenra (Benralizumab): Phase 3 readout est. (NCT07444567)
DESCRIPTION:Fasenra (Benralizumab)\, phase 3\, Asthma.\nStudy: Roll-over St
 udy for Participants Who Have Completed a Previous Clinical Study With Ben
 ralizumab (Fasenra) and Benefit From Continued Treatment\nEstimated primar
 y completion: 27 December 2029. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/benralizumab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07444567
URL:https://assetmemo.bio/drug/benralizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07007312-2835@assetmemo.bio
DTSTAMP:20261121T005007Z
DTSTART;VALUE=DATE:20311130
DTEND;VALUE=DATE:20311201
SUMMARY:Ziftomenib: Phase 3 readout est. (NCT07007312)
DESCRIPTION:Ziftomenib\, phase 3\, Acute Myeloid Leukemia.\nStudy: Studies 
 to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With U
 ntreated NPM1-m or KMT2A-r AML\nEstimated primary completion: November 203
 1. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/ziftomenib#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07007312
URL:https://assetmemo.bio/drug/ziftomenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
